Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1210 in combination with Apatinib or chemotherapy in advanced liver cancer and biliary tract carcinoma
NCT03092895Phase 2Completed
- Sponsor
- Hengrui
- Start
- Apr 2017
- Primary completion
- Mar 2021
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in hepatocellular carcinoma (HCC), biliary tract carcinoma (BTC), sponsored by Hengrui. Started Apr 2017; status: completed.
02
Drugs
camrelizumab
03
Conditions
hepatocellular carcinoma (HCC)biliary tract carcinoma (BTC)
Beyond the preview
Go deeper on NCT03092895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03092895.